Infosys to acquire BASE life science

Infosys has signed a definitive agreement to acquire BASE life science, a leading technology and consulting firm in the life sciences industry in Europe. The acquisition is expected to close during the second quarter of fiscal 2023, subject to customary closing conditions.

BASE brings experts with commercial, medical, digital marketing, clinical, regulatory, and quality know-how to Infosys' domain. Together with Infosys, BASE will further expand its portfolio of expertise into Consumer Health, Animal Health, MedTech and Genomics segments.

Martin Woergaard, CEO, BASE life science, said, “With Infosys as our catalyst, we will be able to accelerate our expansion internationally and create development opportunities for our people. Infosys is a solid, global technology leader, that is a perfect match for ensuring continuous success of BASE while sharing our common purpose and values.”

BASE has about 200 of the finest, multidisciplinary industry experts across Denmark, Switzerland, UK, Germany, France, Italy, and a nearshore technology hub in Spain. It focuses on Data & AI, and the ability to bridge and integrate business logic and technology, driving insights for better health outcomes.

Ravi Kumar S, President, Infosys, said, “This acquisition augments Infosys’ deep life sciences expertise, and expands our footprint further in the Nordics region and across Europe, and scales our digital transformation capabilities with cloud-based industry solutions. We are excited to welcome BASE life science and its leadership team into the Infosys family.”